Author:
Han Yanjie,Lu Haifeng,Gu Zikuan,Guan Peixin,Liu Zhen
Reference61 articles.
1. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;Lancet Oncol.,2015
2. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy;Khalil;Nat. Rev. Clin. Oncol.,2016
3. Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer;Falcomatà;Cancer Discov.,2023
4. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities;Lu;Mol. Cancer,2019
5. Macrophages and metabolism in the tumor microenvironment;Vitale;Cell Metab.,2019